Randall Millikan
Randall Millikan
Dirección de correo verificada de
Citado por
Citado por
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
CN Papandreou, DD Daliani, D Nix, H Yang, T Madden, X Wang, CS Pien, ...
Journal of Clinical Oncology 22 (11), 2108-2121, 2004
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
SM Tu, RE Millikan, B Mengistu, ES Delpassand, RJ Amato, LC Pagliaro, ...
The Lancet 357 (9253), 336-341, 2001
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
AM Aparicio, AL Harzstark, PG Corn, S Wen, JC Araujo, SM Tu, ...
Clinical cancer research 19 (13), 3621-3630, 2013
Multimodality management of urachal carcinoma: the MD Anderson Cancer Center experience
AO Siefker-Radtke, J Gee, YU Shen, S Wen, D Daliani, RE Millikan, ...
The Journal of urology 169 (4), 1295-1298, 2003
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and …
R Millikan, C Dinney, D Swanson, P Sweeney, JY Ro, TL Smith, ...
Journal of Clinical Oncology 19 (20), 4005-4013, 2001
Focus on bladder cancer
CPN Dinney, DJ McConkey, RE Millikan, X Wu, M Bar-Eli, L Adam, ...
Cancer cell 6 (2), 111-116, 2004
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle–control genes
X Wu, J Gu, HB Grossman, CI Amos, C Etzel, M Huang, Q Zhang, ...
The American Journal of Human Genetics 78 (3), 464-479, 2006
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience
AO Siefker-Radtke, CP Dinney, NA Abrahams, C Moran, YU Shen, ...
The Journal of urology 172 (2), 481-484, 2004
A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy …
DJ McConkey, W Choi, YU Shen, IL Lee, S Porten, SF Matin, AM Kamat, ...
European urology 69 (5), 855-862, 2016
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
DB Mendel, RE Schreck, DC West, G Li, LM Strawn, SS Tanciongco, ...
Clinical cancer research 6 (12), 4848-4858, 2000
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
AM Kamat, JR Gee, CPN Dinney, HB Grossman, DA Swanson, ...
The Journal of urology 175 (3), 881-885, 2006
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma
SF Matin, V Margulis, A Kamat, CG Wood, HB Grossman, GA Brown, ...
Cancer 116 (13), 3127-3134, 2010
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
CN Sternberg, SM Donat, J Bellmunt, RE Millikan, W Stadler, P De Mulder, ...
Urology 69 (1), 62-79, 2007
Dose-finding with two agents in phase I oncology trials
PF Thall, RE Millikan, P Mueller, SJ Lee
Biometrics 59 (3), 487-496, 2003
The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy
K Inoue, JW Slaton, T Karashima, C Yoshikawa, T Shuin, P Sweeney, ...
Clinical cancer research 6 (12), 4866-4873, 2000
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
E Jonasch, CG Wood, SF Matin, SM Tu, LC Pagliaro, PG Corn, A Aparicio, ...
Journal of clinical oncology 27 (25), 4076-4081, 2009
Refining patient selection for neoadjuvant chemotherapy before radical cystectomy
SH Culp, RJ Dickstein, HB Grossman, SM Pretzsch, S Porten, ...
The Journal of urology 191 (1), 40-47, 2014
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival
D Leibovici, HB Grossman, CP Dinney, RE Millikan, S Lerner, Y Wang, ...
Journal of clinical oncology 23 (24), 5746-5756, 2005
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center
SP Lynch, Y Shen, A Kamat, HB Grossman, JB Shah, RE Millikan, ...
European urology 64 (2), 307-313, 2013
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
AO Siefker-Radtke, AM Kamat, HB Grossman, DL Williams, W Qiao, ...
Journal of Clinical Oncology 27 (16), 2592-2597, 2009
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20